My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidlines Journals & Publications Policy & Advocacy Meetings About IDSA
May 1, 2008
Cefixime Available Again in the United States

Cefixime 400 mg tablets, currently the only oral treatment for uncomplicated urogenital or rectal Neissesria gonorrhoea recommended by the Centers for Disease Control and Prevention (CDC), is again available in the United States, from Lupin Pharmaceuticals. Information about obtaining cefixime tablets is available by calling Lupin at (866) 587-4617.  Special pricing is available for qualifying public health centers.

The drug was previously manufactured by Wyeth Pharmaceuticals. Production was discontinued in July 2002.

Another cephalosporin, ceftriaxone, available in injection form only, is the CDC recommended treatment for all types of gonorrhea infections.  Treatment guidelines and additional information can be found at http://www.cdc.gov/std/treatment.

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


FDA Lowers Vancomycin Breakpoints for Staph Infections
WHO Reports Progress on Dracunculiasis Eradication
IDSA Literature Review - April 2008
Brazil Has Large Dengue Fever Outbreak
Malaria Reported in Bahamas
Polio Eradication Update: Cases Down Overall, But Type 3 Cases Up
Rift Valley Fever Outbreak in Madagascar
Vietnam Reports Cholera Outbreak
Yellow Fever Reported in Liberia, Argentina
Cefixime Available Again in the United States
Drug Approvals, Recalls, Adverse Events Update
In the IDSA Journals
From the President
IDSA Endorses Two Vaccine Financing Bills
IDSA Urges FDA to Dedicate Resources to Antimicrobial Resistance
Members on the Move
Welcome, New IDSA Members!
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'idsa@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.